A major review of over 26,000 adult patients with salivary gland cancer looked at two treatment paths after surgery. One path used radiation alone, while the other combined radiation with chemotherapy. The goal was to see which approach helped patients live longer.
The researchers found no clear winner. Survival rates were very similar whether patients got radiation alone or the combined treatment. The numbers showed no meaningful difference in overall survival between the two groups.
However, the review had important limits. All the studies it included were based on past medical records, not new experiments. This makes the results less certain. The mix of different cancer types and the way the data was collected also added to the uncertainty.
Because of these limits, doctors cannot say for sure if adding chemotherapy to radiation is better. More research, especially new clinical trials, is needed to find the best treatment for this rare cancer.